Pfizer CSO Mikael Dolsten at #JPM24 (Brian Benton Photography)
July 9, 2024 07:29 AM EDTUpdated 08:50 AM
People

Pfiz­er CSO Mikael Dol­sten to de­part af­ter 15 years lead­ing drug gi­ant's R&D

Kyle LaHucik

Senior Reporter

Mikael Dol­sten, a long­time leader of drug R&D at one of the world’s biggest phar­ma gi­ants, will de­part his post as chief sci­en­tif­ic of­fi­cer at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times